JANX vs. VALU
JANX (Janux Therapeutics, Inc.) and VALU (Value Line, Inc.) are both stocks. JANX operates in Biotechnology (Healthcare), while VALU operates in Financial Data & Stock Exchanges (Financial Services). Over the past 5 years, JANX returned -9.18%/yr vs 5.03%/yr for VALU. At a 0.05 correlation, their price movements are largely independent.
Performance
JANX vs. VALU - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, JANX achieves a 3.91% return, which is significantly higher than VALU's -8.33% return.
JANX
- 1D
- 0.84%
- 1M
- -1.24%
- YTD
- 3.91%
- 6M
- 1.77%
- 1Y
- -39.24%
- 3Y*
- 4.68%
- 5Y*
- -9.18%
- 10Y*
- —
VALU
- 1D
- 1.47%
- 1M
- 4.82%
- YTD
- -8.33%
- 6M
- -9.71%
- 1Y
- -5.84%
- 3Y*
- -7.96%
- 5Y*
- 5.03%
- 10Y*
- 11.30%
JANX vs. VALU - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
JANX Janux Therapeutics, Inc. | 3.91% | -74.22% | 398.97% | -18.53% | -33.25% | -41.97% |
VALU Value Line, Inc. | -8.33% | -24.86% | 11.27% | -1.94% | 10.35% | 42.08% |
Correlation
The correlation between JANX and VALU is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.09 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.05 |
Correlation (All Time) Calculated using the full available price history since Jun 11, 2021 | 0.05 |
Fundamentals
JANX:
$898.63M
VALU:
$324.86M
JANX:
-$1.84
VALU:
$2.34
JANX:
41.23
VALU:
9.62
JANX:
0.95
VALU:
3.01
JANX:
$21.61M
VALU:
$33.83M
JANX:
$8.44M
VALU:
$17.97M
JANX:
-$134.03M
VALU:
$5.80M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
JANX vs. VALU — Risk / Return Rank
JANX
VALU
JANX vs. VALU - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and Value Line, Inc. (VALU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JANX | VALU | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.32 | ||
| Sortino ratioReturn per unit of downside risk | -0.12 | ||
| Omega ratioGain probability vs. loss probability | 0.96 | 0.99 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | -0.61 | -0.33 | -0.28 |
| Martin ratioReturn relative to average drawdown | -0.89 | -0.78 | -0.10 |
Loading charts...
Drawdowns
JANX vs. VALU - Drawdown Comparison
The maximum JANX drawdown since its inception was -83.14%, which is greater than VALU's maximum drawdown of -77.54%. Use the drawdown chart below to compare losses from any high point for JANX and VALU.
Loading charts...
Drawdown Indicators
| JANX | VALU | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.14% | -77.54% | -5.60% |
Max Drawdown (1Y)Largest decline over 1 year | -64.94% | -17.84% | -47.10% |
Max Drawdown (3Y)Largest decline over 3 years | -81.78% | -43.43% | -38.35% |
Max Drawdown (5Y)Largest decline over 5 years | -83.14% | -67.15% | -15.99% |
Max Drawdown (10Y)Largest decline over 10 years | — | -67.15% | — |
Current DrawdownCurrent decline from peak | -78.54% | -61.94% | -16.60% |
Average DrawdownAverage peak-to-trough decline | -52.75% | -33.11% | -19.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.34% | 7.47% | +36.87% |
Volatility
JANX vs. VALU - Volatility Comparison
Janux Therapeutics, Inc. (JANX) has a higher volatility of 9.32% compared to Value Line, Inc. (VALU) at 8.62%. This indicates that JANX's price experiences larger fluctuations and is considered to be riskier than VALU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| JANX | VALU | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.32% | 8.62% | +0.70% |
Volatility (6M)Calculated over the trailing 6-month period | 29.29% | 16.45% | +12.84% |
Volatility (1Y)Calculated over the trailing 1-year period | 73.99% | 27.85% | +46.14% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 130.71% | 60.81% | +69.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 131.25% | 57.63% | +73.62% |
Dividends
JANX vs. VALU - Dividend Comparison
JANX has not paid dividends to shareholders, while VALU's dividend yield for the trailing twelve months is around 3.83%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
JANX Janux Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
VALU Value Line, Inc. | 3.83% | 3.32% | 2.23% | 2.24% | 1.91% | 1.86% | 2.52% | 2.73% | 3.65% | 3.67% | 3.44% | 4.37% |
Financials
JANX vs. VALU - Financials Comparison
This section allows you to compare key financial metrics between Janux Therapeutics, Inc. and Value Line, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
JANX and VALU have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
JANX has higher volatility (9.32%) compared to VALU (8.62%). In terms of maximum drawdown, JANX dropped -83.14% vs VALU's -77.54%.
VALU currently has the higher Sharpe Ratio (-0.21 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for JANX and VALU
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer